A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Description of Business Maravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies. Our comprehensive product portfolio addresses the critical stages of biopharmaceutical development, offering: •complex nucleic acids for therapeutic, vaccine, and diagnostic applications; •custom enzymes for research and diagnostic use; and •antibody-based solutions to detect impurities during the production of biopharmaceutical products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 186M | 186M | 259M | 289M | 883M | 799M |
| Net Income | -131M | -131M | -145M | -119M | 220M | 182M |
| EPS | $-0.90 | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 |
| Free Cash Flow | -71M | -71M | -22M | 61M | 519M | 354M |
| ROIC | -58.1% | -23.5% | -23.5% | -4.6% | 93.7% | 155.4% |
| Gross Margin | 18.3% | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% |
| Debt/Equity | 1.40 | 1.40 | 0.93 | 1.27 | 0.98 | 1.70 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -215M | -215M | -236M | -32M | 574M | 555M |
| Operating Margin | -115.9% | -115.9% | -90.9% | -11.0% | 65.0% | 69.4% |
| ROE | -61.6% | -48.6% | -44.5% | -28.6% | 40.4% | 57.7% |
| Shares Outstanding | 145M | 145M | 138M | 132M | 132M | 251M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 143M | 284M | 799M | 883M | 289M | 259M | 186M | 186M |
| Gross Margin | 53.3% | 72.0% | 82.4% | 80.9% | 48.5% | 41.8% | 18.3% | 18.3% |
| R&D | 3.6M | 9.3M | 15M | 18M | 17M | 19M | 17M | 17M |
| SG&A | 48M | 94M | 100M | 129M | 151M | 162M | 145M | 145M |
| EBIT | 24M | 120M | 555M | 574M | -32M | -236M | -215M | -215M |
| Op. Margin | 16.8% | 42.2% | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% | -115.9% |
| Net Income | -8.5M | 89M | 182M | 220M | -119M | -145M | -131M | -131M |
| Net Margin | -5.9% | 31.3% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% | -70.4% |
| Non-Recurring | 0 | 0 | 11M | 0 | 6.5M | 167M | 61M | 61M |
| Returns on Capital | ||||||||
| ROIC | N/A | 73.8% | 155.4% | 93.7% | -4.6% | -23.5% | -23.5% | -58.1% |
| ROE | N/A | 100.5% | 57.7% | 40.4% | -28.6% | -44.5% | -48.6% | -61.6% |
| ROA | N/A | 7.0% | 9.5% | 9.6% | -8.0% | -14.4% | -14.7% | -17.0% |
| Cash Flow | ||||||||
| Op. Cash Flow | 24M | 152M | 369M | 536M | 126M | 7.5M | -58M | -58M |
| Free Cash Flow | 7.0M | 127M | 354M | 519M | 61M | -22M | -71M | -71M |
| Owner Earnings | -1.6M | 122M | 352M | 485M | 51M | -90M | -139M | -139M |
| CapEx | 17M | 25M | 15M | 17M | 66M | 30M | 13M | 13M |
| Maint. CapEx | 24M | 5.5M | 6.4M | 32M | 40M | 48M | 52M | 52M |
| Growth CapEx | 0 | 20M | 8.4M | 0 | 25M | 0 | 0 | 0 |
| D&A | 24M | 5.5M | 6.4M | 32M | 40M | 48M | 52M | 52M |
| CapEx/OCF | N/A | 16.7% | 4.0% | 3.2% | 51.9% | 397.3% | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 34M | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.5% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.7M | 25M | 10M | 19M | 35M | 49M | 30M | 30M |
| Debt Repayment | 2.5M | 412M | 6.0M | 14M | 5.4M | 234M | 5.4M | 5.4M |
| Balance Sheet | ||||||||
| Net Debt | -25M | 68M | -566M | -731M | -620M | -343M | -137M | 80M |
| Cash & Equiv. | 25M | 236M | 551M | 632M | 575M | 322M | 217M | 217M |
| Long-Term Debt | 0 | 529M | 525M | 522M | 519M | 290M | 286M | 286M |
| Debt/Equity | N/A | 6.11 | 1.70 | 0.98 | 1.27 | 0.93 | 1.40 | 1.40 |
| Interest Coverage | 0.8 | 3.9 | 18.3 | 28.1 | -0.7 | -4.9 | -8.0 | -8.0 |
| Equity | N/A | 89M | 315M | 545M | 417M | 325M | 212M | 212M |
| Total Assets | N/A | 1.3B | 1.9B | 2.3B | 1.5B | 1.0B | 771M | 771M |
| Total Liabilities | N/A | 1.1B | 1.4B | 1.4B | 698M | 431M | 398M | 398M |
| Intangibles | N/A | 178M | 118M | 217M | 221M | 195M | 152M | 152M |
| Retained Earnings | N/A | 854K | 185M | 405M | 286M | 141M | 10M | 10M |
| Working Capital | N/A | 201M | 646M | 738M | 612M | 372M | 251M | 251M |
| Current Assets | N/A | 332M | 740M | 848M | 700M | 429M | 296M | 296M |
| Current Liabilities | N/A | 131M | 94M | 110M | 87M | 57M | 45M | 45M |
| Per Share Data | ||||||||
| EPS | -0.03 | 2.36 | 1.56 | 1.67 | -0.90 | -1.05 | -0.90 | -0.90 |
| Owner EPS | -0.01 | 0.48 | 1.40 | 3.68 | 0.39 | -0.65 | -0.96 | -0.96 |
| Book Value | N/A | 0.35 | 1.26 | 4.13 | 3.15 | 2.36 | 1.46 | 1.46 |
| Cash Flow/Share | 0.09 | 0.60 | 1.47 | 4.06 | 0.95 | 0.05 | -0.40 | -0.55 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 282.9M | 255.2M | 250.9M | 131.9M | 132.3M | 137.9M | 145.3M | 145.3M |
| Valuation | ||||||||
| P/E Ratio | N/A | 12.2 | 26.1 | 8.3 | N/A | N/A | N/A | -3.4 |
| P/FCF | N/A | 58.0 | 28.8 | 3.5 | 14.6 | N/A | N/A | N/A |
| EV/EBIT | N/A | 61.9 | 17.4 | 1.9 | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 83.1 | 32.3 | 3.4 | 2.1 | 2.3 | 2.2 | 2.1 |
| Price/Sales | N/A | 25.0 | 12.6 | 4.0 | 5.2 | 4.1 | 2.3 | 2.4 |
| FCF Yield | N/A | 1.7% | 3.5% | 28.4% | 6.8% | -2.9% | -14.9% | -15.9% |
| Market Cap | N/A | 7.4B | 10.2B | 1.8B | 889M | 759M | 475M | 445M |
| Avg. Price | N/A | 27.87 | 40.17 | 26.79 | 11.36 | 7.64 | 3.00 | 3.06 |
| Year-End Price | N/A | 28.82 | 40.67 | 13.88 | 6.72 | 5.50 | 3.27 | 3.06 |
MARAVAI LIFESCIENCES HOLDINGS, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 39.5% with a gross margin of 54.4%. At current prices, the estimated annualized return to fair value is +3.1%.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a 5-year average return on invested capital (ROIC) of 39.5%. This indicates strong capital allocation and a potential competitive advantage.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a market capitalization of $445M. It is classified as a small-cap stock.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) does not currently pay a regular dividend.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported annual revenue of $186 million in its most recent fiscal year, based on SEC EDGAR filings.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a net profit margin of -70.4%. The company is currently unprofitable.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) generated $-71 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a debt-to-equity ratio of 1.40. This indicates moderate leverage.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported earnings per share (EPS) of $-0.90 in its most recent fiscal year.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a return on equity (ROE) of -48.6%. A negative ROE may indicate losses or negative equity.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a 5-year average gross margin of 54.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) has a book value per share of $1.46, based on its most recent annual SEC filing.